Literature DB >> 17440335

Periareolar skin-sparing mastectomy and latissimus dorsi flap with biodimensional expander implant reconstruction: surgical planning, outcome, and complications.

Alexandre Mendonça Munhoz1, Claudia Aldrighi, Eduardo Montag, Eduardo Gustavo Arruda, José Mendes Aldrighi, José Roberto Filassi, Marcus Castro Ferreira.   

Abstract

BACKGROUND: Although use of the latissimus dorsi myocutaneous flap associated with the Biodimensional anatomical expander implant system (McGhan 150) is a reliable technique, little information has been available regarding clinical outcome following periareolar skin-sparing mastectomy reconstruction. The purpose of this study was to analyze the feasibility of the technique, surgical planning, and its outcome following skin-sparing mastectomy.
METHODS: Thirty-two patients underwent immediate unilateral latissimus dorsi myocutaneous flap/Biodimensional anatomical expander implant system breast reconstruction. Mean follow-up was 18 months. The technique was indicated in patients with small- or moderate-volume breasts with or without ptosis, in whom the use of abdominal flaps was precluded. Flap and donor-site complications were evaluated. Information on anesthetic results and patient satisfaction was collected.
RESULTS: Seventy-two percent had tumors measuring 2 cm or less (T1) and 78 percent were stage 0 and I according to American Joint Committee on Cancer criteria. Breast skin complications occurred in 9.4 percent. Two patients presented small breast skin necrosis, and in one patient, a wound dehiscence was observed. Donor-site complications, all represented by seroma, occurred in 12.5 percent. The cosmetic result was considered good or very good in 84.4 percent, and the majority of patients were either very satisfied or satisfied. No local recurrences were observed. All complications except two were treated by conservative means.
CONCLUSIONS: The latissimus dorsi myocutaneous flap/Biodimensional anatomical expander implant system is a simple and reliable technique for periareolar skin-sparing mastectomy reconstruction. Success depends on patient selection, coordinated planning with the oncologic surgeon, and careful intraoperative and postoperative management.

Entities:  

Mesh:

Year:  2007        PMID: 17440335     DOI: 10.1097/01.prs.0000246406.68739.e4

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  6 in total

1.  Alcohol consumption does not increase the risk of surgical wound complications in breast cancer patients.

Authors:  Raquel Ferreira de Menezes; Anke Bergmann; Luiz Claudio Santos Thuler
Journal:  Int Wound J       Date:  2020-07-27       Impact factor: 3.315

Review 2.  Immediate nipple-areola-sparing mastectomy reconstruction: An update on oncological and reconstruction techniques.

Authors:  Alexandre Mendonça Munhoz; Eduardo Montag; José Roberto Filassi; Rolf Gemperli
Journal:  World J Clin Oncol       Date:  2014-08-10

3.  Single-stage Latissimus Dorsi Breast Reconstruction Using Spectrum Devices: Outcomes and Technique.

Authors:  Colton Boudreau; Kaitlin S Boehm; Aevan MacDonald; Jason Williams
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-05-03

4.  Intramuscular Neural Arborization of the Latissimus Dorsi Muscle: Application of Botulinum Neurotoxin Injection in Flap Reconstruction.

Authors:  Kyu-Ho Yi; Hyung-Jin Lee; Kyle K Seo; Hee-Jin Kim
Journal:  Toxins (Basel)       Date:  2022-01-30       Impact factor: 4.546

5.  Immediate breast reconstruction following segmentectomy using a latissimus dorsi 'myoadipose' flap through a single axillary incision: a case series.

Authors:  Vijay Naraynsingh; Seetharaman Hariharan; Dilip Dan
Journal:  Cases J       Date:  2009-06-11

6.  Skin-sparing mastectomy and immediate latissimus dorsi flap reconstruction: a retrospective analysis of the surgical and patient-reported outcomes.

Authors:  Zisun Kim; Sang Gue Kang; Jung Ho Roh; Ji Hye Park; Jihyoun Lee; SungYong Kim; Cheol Wan Lim; Min Hyuk Lee
Journal:  World J Surg Oncol       Date:  2012-11-29       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.